BOLL
gene geneOn this page
Also known as BOULE
Summary
BOLL (boule RNA binding protein, HGNC:14273) is a protein-coding gene on chromosome 2q33.1, encoding Protein boule-like (Q8N9W6). Probable RNA-binding protein, which may be required during spermatogenesis.
This gene belongs to the DAZ gene family required for germ cell development. It encodes an RNA-binding protein which is more similar to Drosophila Boule than to human proteins encoded by genes DAZ (deleted in azoospermia) or DAZL (deleted in azoospermia-like). Loss of this gene function results in the absence of sperm in semen (azoospermia). Histological studies demonstrated that the primary defect is at the meiotic G2/M transition. Two alternatively spliced transcript variants encoding distinct isoforms have been found for this gene.
Source: NCBI Gene 66037 — RefSeq curated summary.
At a glance
- GWAS associations: 21
- Clinical variants (ClinVar): 46 total
- GTEx eGene: eQTL in 1 tissue, sQTL in 1 (q < 0.05)
- Constraint (gnomAD): pLI 0.31 (intermediate), LOEUF 0.81 (unconstrained)
- MANE Select transcript:
NM_033030
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:14273 |
| Approved symbol | BOLL |
| Name | boule RNA binding protein |
| Location | 2q33.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | BOULE |
| Ensembl gene | ENSG00000152430 |
| Ensembl biotype | protein_coding |
| OMIM | 606165 |
| Entrez | 66037 |
Gene structure
Transcript identifiers
Ensembl transcripts: 8 — 5 protein_coding, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay
MANE Select: ENST00000392296
Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 2, TSL 2: 3, TSL 4: 1, TSL 5: 1
ENST00000392296, ENST00000321801, ENST00000430004, ENST00000433157, ENST00000434976, ENST00000468827, ENST00000486206, ENST00000696103
RefSeq mRNA: 5 — MANE Select: NM_033030
NM_001284358, NM_001284361, NM_001284362, NM_033030, NM_197970
CCDS: CCDS2324, CCDS2325
Canonical transcript exons
ENST00000392296 — 11 exons
| Exon | Start | End |
|---|---|---|
| ENSE00002283182 | 197777059 | 197777113 |
| ENSE00002316144 | 197775665 | 197775740 |
| ENSE00003473014 | 197756428 | 197756556 |
| ENSE00003505764 | 197781722 | 197781865 |
| ENSE00003514990 | 197771855 | 197771982 |
| ENSE00003539782 | 197778975 | 197779066 |
| ENSE00003547716 | 197766532 | 197766603 |
| ENSE00003578526 | 197743061 | 197743159 |
| ENSE00003666160 | 197757353 | 197757400 |
| ENSE00003902208 | 197726890 | 197728578 |
| ENSE00003966008 | 197785056 | 197785319 |
Expression profiles
Bgee: expression breadth broad, 75 present calls, max score 94.82.
FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.2853 / max 284.6346, expressed in 4 samples.
Highest expression (Bgee): testis, adult organism, sperm, buccal mucosa cell, male germ line stem cell (sensu Vertebrata) in testis.
Genetic regulation across tissues (GTEx eQTL / sQTL)
BOLL is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 1 tissue and its splicing (sQTL) in 1 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.
2 significant tissue × QTL associations:
| Tissue | QTL | q-value | Slope | Lead variant |
|---|---|---|---|---|
| Testis | sqtl | 5.8e-40 | -1.25 | 2:197755935:A:C |
| Muscle Skeletal | eqtl | 1.7e-02 | +0.10 | 2:198042419:C:T |
FANTOM5 promoters
7 alternative TSS:
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 33100 | 0.0864 | 3 |
| 33102 | 0.0626 | 3 |
| 33098 | 0.0525 | 3 |
| 33097 | 0.0505 | 3 |
| 33099 | 0.0233 | 3 |
| 33101 | 0.0071 | 4 |
| 33103 | 0.0029 | 2 |
Top tissues by expression
showing 100 of 201 tissues by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| left testis | UBERON:0004533 | 94.82 | gold quality |
| adult organism | UBERON:0007023 | 94.70 | gold quality |
| right testis | UBERON:0004534 | 94.57 | gold quality |
| sperm | CL:0000019 | 93.91 | gold quality |
| testis | UBERON:0000473 | 92.00 | gold quality |
| buccal mucosa cell | CL:0002336 | 90.15 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 81.34 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 78.14 | gold quality |
| tibialis anterior | UBERON:0001385 | 77.96 | silver quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 76.99 | gold quality |
| gastrocnemius | UBERON:0001388 | 71.22 | gold quality |
| muscle of leg | UBERON:0001383 | 71.00 | gold quality |
| ileal mucosa | UBERON:0000331 | 67.76 | silver quality |
| skeletal muscle tissue of biceps brachii | UBERON:0004502 | 67.18 | gold quality |
| skeletal muscle tissue | UBERON:0001134 | 66.45 | gold quality |
| deltoid | UBERON:0001476 | 65.25 | silver quality |
| muscle tissue | UBERON:0002385 | 62.21 | gold quality |
| upper leg skin | UBERON:0004262 | 58.71 | gold quality |
| pancreatic ductal cell | CL:0002079 | 58.70 | silver quality |
| vastus lateralis | UBERON:0001379 | 58.27 | gold quality |
| epithelial cell of pancreas | CL:0000083 | 54.49 | gold quality |
| cardiac muscle of right atrium | UBERON:0003379 | 54.34 | gold quality |
| left ventricle myocardium | UBERON:0006566 | 54.23 | gold quality |
| kidney epithelium | UBERON:0004819 | 53.93 | gold quality |
| upper arm skin | UBERON:0004263 | 53.52 | gold quality |
| cerebellar vermis | UBERON:0004720 | 51.65 | gold quality |
| myocardium | UBERON:0002349 | 50.25 | gold quality |
| nasal cavity epithelium | UBERON:0005384 | 47.03 | gold quality |
| jejunum | UBERON:0002115 | 44.69 | gold quality |
| thymus | UBERON:0002370 | 44.64 | gold quality |
| layer of synovial tissue | UBERON:0007616 | 43.55 | gold quality |
| skeletal muscle tissue of rectus abdominis | UBERON:0004511 | 43.37 | gold quality |
| sural nerve | UBERON:0015488 | 43.11 | gold quality |
| middle temporal gyrus | UBERON:0002771 | 42.60 | gold quality |
| secondary oocyte | CL:0000655 | 42.57 | gold quality |
| superficial temporal artery | UBERON:0001614 | 41.33 | gold quality |
| bone marrow cell | CL:0002092 | 41.19 | gold quality |
| palpebral conjunctiva | UBERON:0001812 | 41.10 | gold quality |
| mucosa of paranasal sinus | UBERON:0005030 | 40.98 | gold quality |
| cartilage tissue | UBERON:0002418 | 40.77 | gold quality |
| amniotic fluid | UBERON:0000173 | 40.69 | gold quality |
| metanephros | UBERON:0000081 | 40.66 | silver quality |
| jejunal mucosa | UBERON:0000399 | 40.59 | gold quality |
| bone marrow | UBERON:0002371 | 40.48 | silver quality |
| epithelium of nasopharynx | UBERON:0001951 | 40.45 | gold quality |
| gingival epithelium | UBERON:0001949 | 40.43 | gold quality |
| germinal epithelium of ovary | UBERON:0001304 | 40.33 | gold quality |
| esophagus squamous epithelium | UBERON:0006920 | 40.29 | gold quality |
| medial globus pallidus | UBERON:0002477 | 40.22 | gold quality |
| epithelium of mammary gland | UBERON:0003244 | 40.14 | gold quality |
| globus pallidus | UBERON:0001875 | 39.99 | gold quality |
| mammary duct | UBERON:0001765 | 39.98 | gold quality |
| mucosa of sigmoid colon | UBERON:0004993 | 39.95 | gold quality |
| saphenous vein | UBERON:0007318 | 39.83 | gold quality |
| parotid gland | UBERON:0001831 | 39.81 | gold quality |
| oocyte | CL:0000023 | 39.80 | gold quality |
| urethra | UBERON:0000057 | 39.80 | gold quality |
| heart right ventricle | UBERON:0002080 | 39.79 | gold quality |
| pericardium | UBERON:0002407 | 39.77 | gold quality |
| endothelial cell | CL:0000115 | 39.75 | gold quality |
| synovial joint | UBERON:0002217 | 39.70 | gold quality |
| dorsal root ganglion | UBERON:0000044 | 39.68 | gold quality |
| nipple | UBERON:0002030 | 39.68 | gold quality |
| bronchial epithelial cell | CL:0002328 | 39.65 | gold quality |
| decidua | UBERON:0002450 | 39.65 | gold quality |
| penis | UBERON:0000989 | 39.64 | gold quality |
| gingiva | UBERON:0001828 | 39.64 | gold quality |
| bronchus | UBERON:0002185 | 39.64 | gold quality |
| trigeminal ganglion | UBERON:0001675 | 39.63 | gold quality |
| tendon of biceps brachii | UBERON:0008188 | 39.60 | gold quality |
| inferior vagus X ganglion | UBERON:0005363 | 39.57 | gold quality |
| colonic mucosa | UBERON:0000317 | 39.56 | gold quality |
| superior surface of tongue | UBERON:0007371 | 39.56 | gold quality |
| pylorus | UBERON:0001166 | 39.55 | gold quality |
| renal medulla | UBERON:0000362 | 39.53 | gold quality |
| skin of hip | UBERON:0001554 | 39.52 | silver quality |
| pons | UBERON:0000988 | 39.51 | gold quality |
| medulla oblongata | UBERON:0001896 | 39.48 | gold quality |
| superior vestibular nucleus | UBERON:0007227 | 39.47 | gold quality |
| cardia of stomach | UBERON:0001162 | 39.46 | gold quality |
| mammalian vulva | UBERON:0000997 | 39.45 | gold quality |
| parietal pleura | UBERON:0002400 | 39.45 | gold quality |
| Brodmann (1909) area 23 | UBERON:0013554 | 39.40 | gold quality |
| dorsal plus ventral thalamus | UBERON:0001897 | 39.38 | gold quality |
| tongue | UBERON:0001723 | 39.37 | gold quality |
| oral cavity | UBERON:0000167 | 39.35 | gold quality |
| subthalamic nucleus | UBERON:0001906 | 39.35 | gold quality |
| ventral tegmental area | UBERON:0002691 | 39.35 | gold quality |
| trachea | UBERON:0003126 | 39.33 | gold quality |
| parietal lobe | UBERON:0001872 | 39.32 | gold quality |
| vena cava | UBERON:0004087 | 39.31 | gold quality |
| pharyngeal mucosa | UBERON:0000355 | 39.27 | gold quality |
| substantia nigra pars compacta | UBERON:0001965 | 39.23 | gold quality |
| visceral pleura | UBERON:0002401 | 39.23 | gold quality |
| postcentral gyrus | UBERON:0002581 | 39.23 | gold quality |
| body of tongue | UBERON:0011876 | 39.22 | gold quality |
| trabecular bone tissue | UBERON:0002483 | 39.18 | gold quality |
| substantia nigra pars reticulata | UBERON:0001966 | 39.11 | gold quality |
| entorhinal cortex | UBERON:0002728 | 39.05 | gold quality |
| lateral nuclear group of thalamus | UBERON:0002736 | 39.00 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 3.71 |
HPA expression
RNA tissue specificity: Tissue enriched
36 HPA tissues / cells by nTPM:
| Tissue / cell | Axis | nTPM | Protein (IHC) |
|---|---|---|---|
| Testis | tissue | 45.7 | high |
| Olfactory bulb | tissue | 4.7 | |
| Cerebellum | tissue | 4.1 | not detected |
| Corpus callosum | tissue | 4.1 | |
| Amygdala | tissue | 3.6 | |
| Skeletal muscle | tissue | 3.5 | not detected |
| Cerebral cortex | tissue | 3.4 | not detected |
| Retrosplenial cortex | tissue | 3.4 | |
| Insular cortex | tissue | 3.4 | |
| Ventral forebrain | tissue | 3.2 | |
| Basal ganglia | tissue | 3.1 | not detected |
| Hippocampal formation | tissue | 3.1 | |
| Retrosplenial and cingulate cortex | tissue | 3.1 | |
| Entorhinal cortex | tissue | 3.0 | |
| Temporal cortex | tissue | 3.0 | |
| Occipital cortex | tissue | 3.0 | |
| Prefrontal cortex | tissue | 2.8 | |
| Putamen | tissue | 2.8 | |
| Periaqueductal gray | tissue | 2.8 | |
| Septum | tissue | 2.8 | |
| Spinal cord | tissue | 2.7 | |
| Motor cortex | tissue | 2.6 | |
| Hypothalamus | tissue | 2.6 | |
| Substantia nigra | tissue | 2.6 | |
| Medulla oblongata | tissue | 2.5 | |
| Somatosensory cortex | tissue | 2.4 | |
| Midbrain | tissue | 2.3 | |
| Thalamus | tissue | 2.1 | |
| Superior colliculi | tissue | 2.1 | |
| Pons | tissue | 1.9 | |
| Tongue | tissue | 1.2 | |
| Postcentral gyrus | tissue | 0.7 | |
| Hippocampus | tissue | 0.6 | not detected |
| Nucleus accumbens | tissue | 0.4 | |
| Locus coeruleus | tissue | 0.4 | |
| Choroid plexus | tissue | 0.2 |
Brain sub-regions (HPA Brain Atlas): detected in 188; highest nTPM — White matter (4.1), Ventral hippocampus (3.1), Subiculum (2.9), Dorsal hippocampus (2.8), Ventral spinal cord (2.7).
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
Targeting BOLL by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).
showing 30 of 114 miRNAs:
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-3646 | 100.00 | 73.56 | 5283 |
| HSA-MIR-4262 | 100.00 | 73.26 | 3931 |
| HSA-MIR-5692A | 100.00 | 74.40 | 6850 |
| HSA-MIR-3163 | 100.00 | 77.23 | 8605 |
| HSA-MIR-4795-3P | 100.00 | 74.62 | 4024 |
| HSA-MIR-4476 | 100.00 | 68.18 | 2030 |
| HSA-MIR-6876-5P | 100.00 | 67.68 | 2126 |
| HSA-MIR-181A-5P | 99.99 | 72.96 | 2995 |
| HSA-MIR-181B-5P | 99.99 | 72.97 | 2996 |
| HSA-MIR-181C-5P | 99.99 | 72.95 | 2996 |
| HSA-MIR-181D-5P | 99.99 | 73.04 | 2997 |
| HSA-MIR-4282 | 99.99 | 75.36 | 6408 |
| HSA-MIR-548C-3P | 99.99 | 74.01 | 7587 |
| HSA-MIR-4775 | 99.98 | 75.00 | 6394 |
| HSA-MIR-548N | 99.98 | 71.94 | 4170 |
| HSA-MIR-548P | 99.98 | 72.25 | 3784 |
| HSA-MIR-302C-5P | 99.97 | 72.56 | 3642 |
| HSA-MIR-3688-3P | 99.97 | 72.02 | 2834 |
| HSA-MIR-590-3P | 99.96 | 74.34 | 6478 |
| HSA-MIR-570-3P | 99.96 | 72.41 | 4910 |
| HSA-MIR-4487 | 99.96 | 64.58 | 1252 |
| HSA-MIR-6825-5P | 99.96 | 69.81 | 3431 |
| HSA-MIR-551B-5P | 99.96 | 71.28 | 3493 |
| HSA-MIR-1-3P | 99.93 | 72.35 | 1914 |
| HSA-MIR-206 | 99.93 | 72.50 | 1893 |
| HSA-MIR-3143 | 99.93 | 71.96 | 3104 |
| HSA-MIR-10527-5P | 99.91 | 72.28 | 3754 |
| HSA-MIR-4648 | 99.91 | 67.00 | 710 |
| HSA-MIR-613 | 99.91 | 71.50 | 1710 |
| HSA-MIR-3671 | 99.90 | 73.04 | 3897 |
Functional genomics
gnomAD constraint: pLI 0.314, LOEUF 0.81, missense Z 0.717 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD
Regional missense constraint (gnomAD RMC): no regional variation along ENST00000392296 — one region, missense o/e 0.85.
Literature-anchored findings (GeneRIF, showing 16)
- BOULE may encode a key conserved switch that regulates progression of germ cells through meiosis in men. (PMID:12499397)
- Role in spermatogenesis. Decreased DAZ proteins in spermatogenic failure may be due to germ cell loss. Transcription of BOULE, DAZL, and DAZ not altered in degrees of spermatogenic failure. No increase of DAZL or BOULE found in DAZ deletion. (PMID:15066460)
- Major group of infertile men with meiotic arrest lack BOULE protein and its putative target, CDC25A expression. Spermatogenic failure may arise from factor(s) upstream of BOULE possibly involved in regulating transcription and/or translation of BOULE. (PMID:15070965)
- BOULE coding sequence mutations are not an important factor in the aetiology of azoospermia. (PMID:15379971)
- mutations in BOULE can be eliminated as a major cause of impaired spermatogenesis. (PMID:15705409)
- Among the three BOULE isoforms, B2 might have the major role for meiotic completion. (PMID:17114206)
- expression of spermatogenic phenotypes of partial AZFc deletions is independent of the variations in DAZL and BOULE in the Han population (PMID:19342699)
- CDC25A is subject to translational control by BOLL, which is an evolutionarily conserved mechanism. (PMID:19417033)
- human DAZL (deleted in azoospermia-like) functions in primordial germ-cell formation, whereas closely related genes DAZ and BOULE (also called BOLL) promote later stages of meiosis and development of haploid gametes (PMID:19865085)
- Assessing the expression of both CDY1 and BOULE by qualitative RT-PCR is a sensitive and feasible test for predicting the presence of sperm cells in testicular tissue biopsies. (PMID:21474125)
- demonstrate that Boll is also transiently expressed during oogenesis in the fetal mouse ovary, but is simultaneously co-expressed within the same germ cells as Dazl (PMID:24086306)
- Our study demonstrated an oncogenic role of BOLL in CRC despite tumor-specific promoter hypermethylation. (PMID:25605553)
- hypermethylation of DAZL and BOULE promoters in human sperm is associated with human infertility (PMID:27358391)
- Four sterility-related genes, including BOLL, DDX4, HORMAD1, and MAEL, were found to have increased methylation at CpGs of the promoter regions and decreased mRNA expressions in nonobstructive azoospermia and hypospermatogenesis (HS) testis and are believed to be associated with HS. (PMID:28342926)
- Direct reprogramming of human Sertoli cells into male germline stem cells with the self-renewal and differentiation potentials via overexpressing DAZL/DAZ2/BOULE genes. (PMID:34653405)
- Novel Mutations Reduce Expression of Meiotic Regulators SYCE1 and BOLL in Testis of Azoospermic Men from West Bengal, India. (PMID:37957469)
Cross-species orthologs
3 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | Boll | ENSMUSG00000025977 |
| rattus_norvegicus | Boll | ENSRNOG00000054379 |
| drosophila_melanogaster | bol | FBGN0011206 |
Paralogs (5): DAZL (ENSG00000092345), DAZ3 (ENSG00000187191), DAZ1 (ENSG00000188120), DAZ4 (ENSG00000205916), DAZ2 (ENSG00000205944)
Mouse-model phenotypes
Observed phenotypes of the mouse ortholog (MGI:1922638) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 10 distinct phenotype terms.
| Mouse phenotype (MP) | Records |
|---|---|
| small testis | 1 |
| arrest of spermatogenesis | 1 |
| abnormal spermatogenesis | 1 |
| male infertility | 1 |
| abnormal spermiogenesis | 1 |
| decreased testis weight | 1 |
| azoospermia | 1 |
| arrest of spermiogenesis | 1 |
| abnormal male germ cell apoptosis | 1 |
| multinucleated giant male germ cells | 1 |
Additional cross-species homologs
Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.
| Organism | UniProt | Identity | Method |
|---|---|---|---|
| Pongo abelii | Q5R8Y8 | 100.0% | Diamond |
| Gallus gallus | Q7T2T1 | 99.8% | Diamond |
| Xenopus laevis | O57437 | 99.3% | Diamond |
| Macaca fascicularis | Q8WP23 | 98.9% | Diamond |
| Xenopus tropicalis | A4IIM2 | 96.8% | Diamond |
| Callithrix jacchus | Q9BGN8 | 94.9% | Diamond |
| Bos taurus | Q32LC7 | 93.8% | Diamond |
| Danio rerio | Q6P0B1 | 92.6% | Diamond |
| Oryza sativa Japonica Group | Q6Z358 | 90.9% | Diamond |
| Arabidopsis thaliana | P92964 | 75.4% | Diamond |
| Schizosaccharomyces pombe 972h- | O42847 | 57.6% | Diamond |
| Caenorhabditis elegans | Q20870 | 49.1% | Diamond |
| Saccharomyces cerevisiae S288C | P53927 | 46.5% | Diamond |
| Ophiostoma ulmi | Q01491 | 38.0% | Diamond |
Genomic neighbors (locus context)
Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).
| Symbol | Type | Entrez |
|---|---|---|
| LINC01923 | ncRNA | 101927619 |
| PLCL1 | protein-coding | 5334 |
| MARS2 | protein-coding | 92935 |
| HSPE1-MOB4 | protein-coding | 100529241 |
| RFTN2 | protein-coding | 130132 |
| MOB4 | protein-coding | 25843 |
| HSPE1 | protein-coding | 3336 |
Protein
Protein identifiers
Protein boule-like — Q8N9W6 (reviewed: Q8N9W6)
All UniProt accessions (4): Q8N9W6, A0A8Q3WL03, F2Z2G3, F8WD91
UniProt curated annotations — full annotation on UniProt →
Function. Probable RNA-binding protein, which may be required during spermatogenesis. May act by binding to the 3’-UTR of mRNAs and regulating their translation.
Subunit / interactions. Interacts with DAZ1 and DAZL.
Subcellular location. Cytoplasm.
Tissue specificity. Testis specific. Not expressed in early embryos, primordial germ cells and spermatogonial cells. First expressed in the cytoplasm of spermatocytes and then persists through meiosis.
Similarity. Belongs to the RRM DAZ family.
Isoforms (5)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q8N9W6-1 | 1, BOULE2 | yes |
| Q8N9W6-2 | 2 | |
| Q8N9W6-3 | 3, BOULE1 | |
| Q8N9W6-4 | 4, BOULE3 | |
| Q8N9W6-5 | 5 |
RefSeq proteins (5): NP_001271287, NP_001271290, NP_001271291, NP_149019, NP_932074 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000504 | RRM_dom | Domain |
| IPR012677 | Nucleotide-bd_a/b_plait_sf | Homologous_superfamily |
| IPR035979 | RBD_domain_sf | Homologous_superfamily |
| IPR043628 | DAZ_dom | Domain |
Pfam: PF00076
UniProt features (11 total): splice variant 6, domain 2, chain 1, sequence conflict 1, region of interest 1
Structure
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q8N9W6-F1 | 64.18 | 0.25 |
Human Protein Atlas
Protein class: Predicted intracellular proteins
Protein evidence: Evidence at protein level
Subcellular location (HPA, imaging): annulus; end piece; mid piece; principal piece
Antibody reliability (HPA): IH enhanced · IF approved
Function
Pathways and Gene Ontology
Reactome pathways
0 curated (TAS) of 0; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).
MSigDB gene sets: 118 (showing top):
GOBP_REGULATION_OF_MRNA_CATABOLIC_PROCESS, ATACCTC_MIR202, GOBP_3_UTR_MEDIATED_MRNA_STABILIZATION, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_TRANSLATIONAL_INITIATION, GOBP_MALE_GAMETE_GENERATION, GOBP_TRANSLATION, GOBP_POSITIVE_REGULATION_OF_TRANSLATIONAL_INITIATION, GOBP_POST_TRANSCRIPTIONAL_REGULATION_OF_GENE_EXPRESSION, GOMF_TRANSLATION_REGULATOR_ACTIVITY, GOBP_REGULATION_OF_CATABOLIC_PROCESS, BROWN_MYELOID_CELL_DEVELOPMENT_UP, GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION, WEBER_METHYLATED_HCP_IN_SPERM_UP, WEBER_METHYLATED_HCP_IN_FIBROBLAST_DN
GO Biological Process (6): spermatogenesis (GO:0007283), cell differentiation (GO:0030154), positive regulation of translational initiation (GO:0045948), meiotic cell cycle (GO:0051321), 3’-UTR-mediated mRNA stabilization (GO:0070935), regulation of translation (GO:0006417)
GO Molecular Function (6): mRNA 3’-UTR binding (GO:0003730), translation activator activity (GO:0008494), identical protein binding (GO:0042802), nucleic acid binding (GO:0003676), RNA binding (GO:0003723), protein binding (GO:0005515)
GO Cellular Component (1): cytoplasm (GO:0005737)
GO top-level categories
21 GO namespaces:
| Category | Terms |
|---|---|
| positive regulation of translation | 2 |
| binding | 2 |
| developmental process involved in reproduction | 1 |
| male gamete generation | 1 |
| cellular developmental process | 1 |
| translational initiation | 1 |
| regulation of translational initiation | 1 |
| cell cycle | 1 |
| sexual reproduction | 1 |
| reproductive process | 1 |
| meiotic nuclear division | 1 |
| mRNA stabilization | 1 |
| translation | 1 |
| post-transcriptional regulation of gene expression | 1 |
| regulation of protein metabolic process | 1 |
| mRNA binding | 1 |
| translation regulator activity | 1 |
| protein binding | 1 |
| nucleic acid binding | 1 |
| intracellular anatomical structure | 1 |
| cellular anatomical structure | 1 |
Experimentally-supported GO annotations
GO terms backed by direct experimental evidence (ECO experimental codes) — 5 of 13 annotations. The rest are phylogenetic / computational / electronic (IEA).
5 experimentally-supported GO terms:
| GO term | NS | Evidence |
|---|---|---|
| meiotic cell cycle | BP | direct assay |
| positive regulation of translational initiation | BP | direct assay |
| cytoplasm | CC | direct assay |
| identical protein binding | MF | physical interaction |
| translation activator activity | MF | direct assay |
Protein interactions and networks
STRING
showing 15 of 954 interactions by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| BOLL | DAZAP2 | Q15038 | 797 |
| BOLL | CDC25A | P30304 | 745 |
| BOLL | DDX4 | Q9NQI0 | 733 |
| BOLL | SYCP3 | Q8IZU3 | 710 |
| BOLL | ACR | P10323 | 656 |
| BOLL | CDC25B | P30305 | 531 |
| BOLL | TEKT1 | Q969V4 | 531 |
| BOLL | STRA8 | Q7Z7C7 | 501 |
| BOLL | DRC11L | A6NCM1 | 491 |
| BOLL | GDF9 | O60383 | 486 |
| BOLL | NANOS3 | P60323 | 484 |
| BOLL | SPATA22 | Q8NHS9 | 476 |
| BOLL | CNOT7 | Q9UIV1 | 457 |
| BOLL | BMP15 | O95972 | 456 |
| BOLL | ASZ1 | Q8WWH4 | 453 |
IntAct
Human interaction partners of BOLL in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).
12 partners by confidence:
| Partner | Interaction type | MIscore | Records |
|---|---|---|---|
| ZNF385C | physical association | 0.680 | 4 |
| HNRNPLL | physical association | 0.670 | 4 |
| RBFOX2 | physical association | 0.670 | 4 |
| TFG | physical association | 0.610 | 4 |
| C1orf94 | physical association | 0.560 | 3 |
| NPBWR2 | physical association | 0.560 | 3 |
| RBPMS | physical association | 0.560 | 3 |
| DAZ1 | physical association | 0.550 | 2 |
| PUM2 | physical association | 0.510 | 3 |
| DAZL | physical association | 0.370 | 1 |
| SERF2 | physical association | 0.370 | 1 |
| ACY1 | association | 0.350 | 1 |
BioGRID (53 interactions; top human partners by supporting records): ACY1 (Affinity Capture-MS; 3 records), CDC20B (Affinity Capture-MS; 3 records), UBA5 (Affinity Capture-MS; 3 records), C1orf94 (Two-hybrid; 2 records), RBFOX2 (Two-hybrid; 2 records), TFG (Two-hybrid; 2 records), ZNF385C (Two-hybrid; 2 records), AGRN (Two-hybrid), ARID5A (Two-hybrid), ATXN2L (Two-hybrid), C4orf45 (Two-hybrid), CBX2 (Two-hybrid), DAZ1 (Two-hybrid), DCANP1 (Two-hybrid), EHHADH (Two-hybrid)
Disease & clinical
Genetic variants
Variant evidence for BOLL: 46 ClinVar records (0 pathogenic / likely pathogenic); 21 GWAS associations.
ClinVar
46 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 38 |
| Likely benign | 0 |
| Benign | 0 |
SpliceAI
Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 33 predictions of 1,314):
| Position(s) | Effect | Δscore | Sites |
|---|---|---|---|
| 2:197743059–197743060 | donor_loss | 1.0000 | 4 |
| 2:197743160–197743161 | acceptor_loss | 1.0000 | 6 |
| 2:197743163 | acceptor_gain | 1.0000 | |
| 2:197756426–197756427 | donor_loss | 1.0000 | 4 |
| 2:197743059–197743060 | donor_loss | 0.9900 | 2 |
| 2:197743167 | acceptor_gain | 0.9900 | |
| 2:197757351–197757352 | donor_loss | 0.9900 | 5 |
| 2:197769508 | acceptor_gain | 0.9900 | |
| 2:197771850 | donor_loss | 0.9900 | 3 |
| 2:197771853–197771854 | donor_loss | 0.9900 | 6 |
AlphaMissense
523 missense substitutions predicted likely pathogenic (of 1,822 scored), across 115 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:
| Residue | Likely-pathogenic substitutions | Mean am_pathogenicity | Max am_pathogenicity |
|---|---|---|---|
| F77 | 8 | 0.997 | 1.000 |
| F36 | 8 | 0.994 | 1.000 |
| F53 | 8 | 0.993 | 0.999 |
| D67 | 8 | 0.991 | 0.998 |
| F80 | 8 | 0.971 | 1.000 |
| F147 | 8 | 0.931 | 0.996 |
| D41 | 8 | 0.898 | 0.975 |
| N104 | 8 | 0.846 | 0.984 |
| F52 | 7 | 0.910 | 0.995 |
| I40 | 7 | 0.815 | 0.998 |
| K73 | 6 | 1.000 | 1.000 |
| G74 | 6 | 0.998 | 1.000 |
| G57 | 6 | 0.994 | 1.000 |
| K111 | 6 | 0.993 | 0.999 |
| R34 | 6 | 0.991 | 1.000 |
| A108 | 6 | 0.989 | 1.000 |
| K63 | 6 | 0.986 | 0.998 |
| K101 | 6 | 0.983 | 0.997 |
| V59 | 6 | 0.978 | 0.999 |
| G76 | 6 | 0.969 | 1.000 |
HPA cancer prognostics
RNA cancer specificity: Low cancer specificity
Disease associations
OMIM: gene MIM:606165 | disease phenotypes:
GWAS associations
21 associations:
| Study | Trait | p-value |
|---|---|---|
| GCST010701_19 | Cortical surface area (MOSTest) | 2e-37 |
| GCST007565_181 | Morning person | 1e-27 |
| GCST006803_15 | Schizophrenia | 4e-13 |
| GCST010702_115 | Subcortical volume (MOSTest) | 1e-11 |
| GCST010703_247 | Brain morphology (MOSTest) | 1e-11 |
| GCST002539_26 | Schizophrenia | 2e-11 |
| GCST004521_281 | Autism spectrum disorder or schizophrenia | 3e-11 |
| GCST007293_132 | Body fat distribution (arm fat ratio) | 8e-11 |
| GCST010700_25 | Cortical thickness (MOSTest) | 2e-10 |
| GCST010699_54 | Brain morphology (min-P) | 1e-9 |
| GCST007294_2 | Body fat distribution (trunk fat ratio) | 3e-9 |
| GCST004521_50 | Autism spectrum disorder or schizophrenia | 7e-9 |
| GCST010698_56 | Subcortical volume (min-P) | 2e-8 |
| GCST010730_2 | Rheumatoid arthritis | 2e-8 |
| GCST009720_13 | Asthma | 3e-8 |
| GCST000262_1 | Intracranial aneurysm | 4e-8 |
| GCST004132_10 | Crohn’s disease | 7e-8 |
| GCST007293_87 | Body fat distribution (arm fat ratio) | 2e-7 |
| GCST007293_51 | Body fat distribution (arm fat ratio) | 1e-6 |
| GCST007294_134 | Body fat distribution (trunk fat ratio) | 4e-6 |
| GCST005588_16 | Idiopathic dilated cardiomyopathy | 9e-6 |
EFO canonical traits (from GWAS)
5 canonical traits:
| EFO ID | Trait name |
|---|---|
| EFO:0009094 | idiopathic dilated cardiomyopathy |
| EFO:0004341 | body fat distribution |
| EFO:0008328 | chronotype measurement |
| EFO:0004346 | neuroimaging measurement |
| EFO:0004840 | cortical thickness |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (CPIC guideline: no)
CTD chemical–gene interactions
11 total (human), top 11 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| bisphenol A | decreases expression | 1 |
| CGP 52608 | affects binding, increases reaction | 1 |
| (((4-nitrophenyl)amino)(2,2,4,4-tetramethyl thiochroman-6-yl)amino) methane-1-thione | increases expression | 1 |
| bisphenol S | affects cotreatment, decreases methylation | 1 |
| Irinotecan | affects cotreatment, increases response to substance | 1 |
| Fulvestrant | affects cotreatment, decreases methylation | 1 |
| Amiodarone | increases expression | 1 |
| Benzo(a)pyrene | decreases methylation, increases methylation | 1 |
| Leucovorin | affects cotreatment, increases response to substance | 1 |
| Fluorouracil | affects cotreatment, increases response to substance | 1 |
| Valproic Acid | increases methylation | 1 |
Clinical trials (associated diseases)
Via MONDO — disease-level, not drug-specific.
Related Atlas pages
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): brain aneurysm, rheumatoid arthritis